Evidence map›Paper›PMID 36048155›Full record

ArticleActa crystallographica. Section D, Structural biology2022

Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution.

Elena Erausquin, Fabian Glaser, Juan Fernández-Recio, Jacinto López-Sagaseta

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elena ErausquinUnit of Protein Crystallography and Structural Immunology, Navarrabiomed, Pamplona 31008, Spain.ORCID 0000-0003-1560-9671
Fabian GlaserThe Lorry I. Lokey Center for Life Sciences and Engineering, Technion - Israel Institute of Technology, Haifa, Israel.
Juan Fernández-RecioInstituto de Ciencias de la Vid y del Vino (ICVV), CSIC-UR-Gobierno de La Rioja, Logroño, Spain.ORCID 0000-0002-3986-7686
Jacinto López-SagasetaUnit of Protein Crystallography and Structural Immunology, Navarrabiomed, Pamplona 31008, Spain.ORCID 0000-0002-7774-4361

Funding

Agencia Estatal de Investigación PID2019-110167RB-I00Gobierno de Navarra 0011-3597-2020-000010Israel Science Foundation 2106/20Ministerio de Ciencia e Innovación 0011-1408-2021-000023Ministerio de Ciencia e Innovación RYC-2017-21683
6 · The paper itself

Abstract

A remarkable number of SARS-CoV-2 variants and other as yet unmonitored lineages harbor amino-acid substitutions with the potential to modulate the interface between the spike receptor-binding domain (RBD) and its receptor ACE2. The naturally occurring Q498Y substitution, which is present in currently circulating SARS-CoV-2 variants, has drawn the attention of several investigations. While computational predictions and in vitro binding studies suggest that Q498Y increases the binding affinity of the spike protein for ACE2, experimental in vivo models of infection have shown that a triple mutant carrying the Q498Y replacement is fatal in mice. To accurately characterize the binding kinetics of the RBD Q498Y-ACE2 interaction, biolayer interferometry analyses were performed. A significant enhancement of the RBD-ACE2 binding affinity relative to a reference SARS-CoV-2 variant of concern carrying three simultaneous replacements was observed. In addition, the RBD Q498Y mutant bound to ACE2 was crystallized. Compared with the structure of its wild-type counterpart, the RBD Q498Y-ACE2 complex reveals the conservation of major hydrogen-bond interactions and a more populated, nonpolar set of contacts mediated by the bulky side chain of Tyr498 that collectively lead to this increase in binding affinity. In summary, these studies contribute to a deeper understanding of the impact of a relevant mutation present in currently circulating SARS-CoV-2 variants which might lead to stronger host-pathogen interactions.

Indexed as

COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsBinding SitesHumansMicePeptidyl-Dipeptidase AProtein BindingSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase ASpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2 receptorbinding affinityCOVID-19RBD–ACE2 complexSARS-CoV-2spike protein Q498Y mutationspike protein receptor binding domainX-ray structure

Identifiers

PMID36048155
PMCPMC9435600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.